A pMHC-specific CD8 + T cell approach has the most clinically-proven benefit in AML of delivering a cell product that can persist in circulation while also maintaining a central memory phenotype with inducible cytotoxicity (11, 12, 42). The gene discussed is CD8A; the disease is acute myeloid leukemia.